March 3, 2026Open Access

Vaginal tamoxifen – A potential treatment option for vaginal atrophy symptoms in postmenopausal women who cannot use estrogen

Key Points

More than two-thirds of women reported relief from troublesome vaginal atrophy symptoms with tamoxifen use, showing its potential effectiveness.
Evidence indicates that tamoxifen's estrogen agonistic effects in the vagina may play a key role in these improvements under low-estrogen conditions.
This observational analysis highlights the need for improved vaginal administration techniques to enhance treatment effects.
Endometrial safety concerns remain, emphasizing the necessity for further studies to address potential risks.

Abstract

This study has demonstrated that more than two-thirds of the women on vaginal tamoxifen improved in their most troublesome VVA symptom. This is likely due to a tamoxifen-induced estrogen agonistic effects in vagina in a low-estrogen environment. While findings are promising, further studies on improved vaginal administration and endometrial safety concerns are needed.

Vaginal tamoxifen – A potential treatment option for vaginal atrophy symptoms in postmenopausal women who cannot use estrogen

Key Points

Abstract

Cite This Study